As the push continues to create a vaccination for COVID-19, Morehouse School of Medicine (MSM) is conducting two novel coronavirus-related clinical trials.
As MSM’s clinical trials are happening locally, Pfizer and Moderna recently announced promising results from their Phase 3 trials. According to Pfizer, their vaccine appears to be more than 90% effective and Moderna’s vaccine appears to be 94.5% effective.
Lilly Immergluck, an associate professor of microbiology, biochemistry, immunology and pediatrics and the director of the Pediatric Clinical & Translational Research Unit, Clinical Research Center, joined Monday’s edition of “Closer Look.”
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
